Functional expression of TLR9 in esophageal cancer

Zhang,Yanli; Wang,Qiuyan; Ma,Ailing; Li,Yunhong; Li,Rui; Wang,Yin

doi:10.3892/or.2014.3095

Functional expression of TLR9 in esophageal cancer

Authors:
- Yanli Zhang
- Qiuyan Wang
- Ailing Ma
- Yunhong Li
- Rui Li
- Yin Wang
View Affiliations

Affiliations: Basic Medical College, Center of Scientific Technology, Ningxia Medical University, Ningxia Key Laboratory of Cerebrocranial Diseases, Yinchuan, Ningxia 750004, P.R. China, The General Hospital of Ningxia Medical University, Yinchuan, Ningxia 750004, P.R. China
Published online on: March 19, 2014 https://doi.org/10.3892/or.2014.3095
Pages: 2298-2304

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The Toll-like receptor 9 (TLR9) plays a crucial role in both innate and adaptive immune responses against infection and danger signals. Stimulation of TLR9 has been linked to invasion in various cancer cells in vitro. The present study evaluated the expression of TLR9 in human esophageal cancer (EC) cells and normal and malignant esophageal squamous epithelium, and examined the association between TLR9 expression, clinicopathological variables, and EC patient outcome. We further characterized the direct effects of TLR9 agonist CpG oligonucleotides (CpG ODN) and inhibitor chloroquine (CQ), on the proliferation and invasion of EC cells in vitro. RT-PCR, western blot, flow cytometry and immunohistochemical analysis were used to determine the expression of TLR9 in EC cell line TE10, and 90 cases of esophageal squamous cell carcinoma, including 30 cases of adjacent esophageal epithelium. The TLR9 expression was compared with tumor size, location, grade, stage and proliferation. We found basal expression of TLR9 in TE10 cells. Esophageal carcinomas exhibited TLR9 expression that was positively associated with tumor size, location and TNM stage (P<0.05). CpG ODN significantly enhanced the invasion of TE10 cells, which could be abrogated by a TLR9 inhibitor CQ. CpG ODN led to activation of NF‑κB and enhanced expression of matrix metalloproteinase (MMP)-2, MMP-7 and cyclooxygenase-2 (COX-2) mRNA. Expression of TLR9 in EC suggests a role of TLR9 related to cell proliferation and differentiation. Our findings indicate that TLR9 may represent a novel therapeutic target in this disease.

View Figures

View References

1	He J, Gu D, Wu X, Reynolds K, Duan X, Yao C, Wang J, Chen CS, Chen J, Wildman RP, Klag MJ and Whelton PK: Major causes of death among men and women in China. N Engl J Med. 353:1124–1134. 2005. View Article : Google Scholar : PubMed/NCBI
2	Fukata M and Abreu MT: Pathogen recognition receptors, cancer and inflammation in the gut. Curr Opin Pharmacol. 9:680–687. 2009. View Article : Google Scholar : PubMed/NCBI
3	Takeda K and Akira S: Microbial recognition by Toll-like receptors. J Dermatol Sci. 34:73–82. 2004. View Article : Google Scholar
4	Underhill DM: Toll-like receptors: networking for success. Eur J Immunol. 33:1767–1775. 2003. View Article : Google Scholar : PubMed/NCBI
5	Barton GM and Medzhitov R: Toll-like receptor signaling pathways. Science. 300:1524–1525. 2003. View Article : Google Scholar : PubMed/NCBI
6	Takeda K, Kaisho T and Akira S: Toll-like receptors. Annu Rev Immunol. 21:335–376. 2003. View Article : Google Scholar
7	Wagner H: The immunobiology of the TLR9 subfamily. Trends Immunol. 25:381–386. 2004. View Article : Google Scholar : PubMed/NCBI
8	Merrell MA, Ilvesaro JM, Lehtonen N, Sorsa T, Gehrs B, Rosenthal E, Chen D, Shackley B, Harris KW and Selander KS: Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol Cancer Res. 4:437–447. 2006. View Article : Google Scholar : PubMed/NCBI
9	Berger R, Fiegl H, Goebel G, Obexer P, Ausserlechner M, Doppler W, Hauser-Kronberger C, Reitsamer R, Egle D, Reimer D, Müller-Holzner E, Jones A and Widschwendter M: Toll-like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumors. Cancer Sci. 101:1059–1066. 2010. View Article : Google Scholar : PubMed/NCBI
10	Ilvesaro JM, Merrell MA, Swain TM, Davidson J, Zayzafoon M, Harris KW and Selander KS: Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro. Prostate. 67:774–781. 2007. View Article : Google Scholar : PubMed/NCBI
11	Ren T, Xu L, Jiao S, Wang Y, Cai Y, Liang Y, Zhou Y, Zhou H and Wen Z: Tlr9 signaling promotes tumor progression of human lung cancer cell in vivo. Pathol Oncol Res. 15:623–630. 2009. View Article : Google Scholar : PubMed/NCBI
12	Tanaka J, Sugimoto K, Shiraki K, Tameda M, Kusagawa S, Nojiri K, Beppu T, Yoneda K, Yamamoto N, Uchida K, Kojima T and Takei Y: Functional cell surface expression of toll-like receptor 9 promotes cell proliferation and survival in human hepatocellular carcinomas. Int J Oncol. 37:805–814. 2010.PubMed/NCBI
13	Wang C, Cao S, Yan Y, Ying Q, Jiang T, Xu K and Wu A: TLR9 expression in glioma tissues correlated to glioma progression and the prognosis of GBM patients. BMC Cancer. 10:415–426. 2010. View Article : Google Scholar : PubMed/NCBI
14	Jukkola-Vuorinen A, Rahko E, Vuopala KS, Desmond R, Lehenkari PP, Harris KW and Selander KS: Toll-like receptor-9 expression is inversely correlated with estrogen receptor status in breast cancer. J Innate Immun. 1:59–68. 2008. View Article : Google Scholar : PubMed/NCBI
15	González-Reyes S, Marín L, González L, González LO, del Casar JM, Lamelas ML, González-Quintana JM and Vizoso FJ: Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis. BMC Cancer. 10:665–673. 2010.PubMed/NCBI
16	Wu HQ, Wang B, Zhu SK, Tian Y, Zhang JH and Wu HS: Effects of CPG ODN on biological behavior of PANC-1 and expression of TLR9 in pancreatic cancer. World J Gastroenterol. 17:996–1003. 2011.PubMed/NCBI
17	Droemann D, Albrecht D, Gerdes J, Ulmer AJ, Branscheid D, Vollmer E, Dalhoff K, Zabel P and Goldmann T: Human lung cancer cells express functionally active Toll-like receptor 9. Respir Res. 6:1–10. 2005. View Article : Google Scholar : PubMed/NCBI
18	Zeromski J, Mozer-Lisewska I and Kaczmarek M: Significance of Toll-like receptors expression in tumor growth and spreading: a short review. Cancer Microenviron. 1:37–42. 2008. View Article : Google Scholar : PubMed/NCBI
19	Jurk M and Vollmer J: Therapeutic applications of synthetic CpG oligodeoxynucleotides as TLR9 agonists for immune modulation. BioDrugs. 21:387–401. 2007. View Article : Google Scholar : PubMed/NCBI
20	Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K and Akira S: A Toll-like receptor recognizes bacterial DNA. Nature. 408:740–745. 2000. View Article : Google Scholar : PubMed/NCBI
21	Takeshita F, Gursel I, Ishii KJ, Suzuki K, Gursel M and Klinman DM: Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like receptor 9. Semin Immunol. 16:17–22. 2004. View Article : Google Scholar : PubMed/NCBI
22	Kuo CC, Kuo CW, Liang CM and Liang SM: A transcriptomic and proteomic analysis of the effect of CpG-ODN on human THP-1 monocytic leukemia cells. Proteomics. 5:894–906. 2005. View Article : Google Scholar : PubMed/NCBI
23	Kostjuk S, Loseva P, Chvartatskaya O, Ershova E, Smirnova T, Malinovskaya E, Roginko O, Kuzmin V, Izhevskaia V, Baranova A, Ginter E and Veiko N: Extracellular GC-rich DNA activates TLR9- and NF-κB-dependent signaling pathways in human adipose-derived mesenchymal stem cells (haMSCs). Expert Opin Biol Ther. 12(Suppl 1): S99–S111. 2012.PubMed/NCBI
24	Zhao H, Dong Y, Tian X, Tan TK, Liu Z, Zhao Y, Zhang Y, Harris DCh and Zheng G: Matrix metalloproteinases contribute to kidney fibrosis in chronic kidney diseases. World J Nephrol. 2:84–89. 2013. View Article : Google Scholar : PubMed/NCBI
25	Folgueras AR, Pendas AM, Sanchez LM and Lopez-Otin C: Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol. 48:411–424. 2004. View Article : Google Scholar : PubMed/NCBI
26	Zeng ZS, Cohen AM and Guillem JG: Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during human colorectal tumorigenesis. Carcinogenesis. 20:749–755. 1999. View Article : Google Scholar : PubMed/NCBI
27	Bartsch JE, Staren ED and Appert HE: Matrix metalloproteinase expression in breast cancer. J Surg Res. 110:383–392. 2003. View Article : Google Scholar : PubMed/NCBI
28	Jezierska A and Motyl T: Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review. Med Sci Monit. 15:RA32–RA40. 2009.PubMed/NCBI
29	Sims JD, McCready J and Jay DG: Extracellular heat shock protein (Hsp)70 and Hsp90 alpha assist in matrix metalloproteinase-2 activation and breast cancer cell migration and invasion. PLoS One. 6:e188482011. View Article : Google Scholar : PubMed/NCBI
30	Lee KH, Shin SJ, Kim KO, Kim MK, Hyun MS, Kim TN, Jang BI, Kim SW, Song SK, Kim HS, Bae SH and Ryoo HM: Relationship between E-cadherin, matrix metalloproteinase-7 gene expression and clinicopathological features in gastric carcinoma. Oncol Rep. 16:823–830. 2006.PubMed/NCBI
31	Okayama H, Kumamoto K, Saitou K, Hayase S, Kofunato Y, Sato Y, Miyamoto K, Nakamura I, Ohki S, Sekikawa K and Takenoshita S: CD44v6, MMP-7 and nuclear Cdx2 are significant biomarkers for prediction of lymph node metastasis in primary gastric cancer. Oncol Rep. 22:745–755. 2009.PubMed/NCBI
32	Yeh YC, Sheu BS, Cheng HC, Wang YL, Yang HB and Wu JJ: Elevated serum matrix metalloproteinase-3 and -7 in H. pylori-related gastric cancer can be biomarkers correlating with a poor survival. Dig Dis Sci. 55:1649–1657. 2010.PubMed/NCBI
33	Sugie S, Tsukino H, Mukai S, Akioka T, Shibata N, Nagano M and Kamoto T: Cyclooxygenase 2 genotypes influence prostate cancer susceptibility in Japanese men. Tumour Biol. Nov 8–2013.(Epub ahead of print).
34	Lu J, Li XF, Kong LX, Ma L, Liao SH and Jiang CY: Expression and significance of cyclooxygenase-2 mRNA in benign and malignant ascites. World J Gastroenterol. 19:6883–6887. 2013. View Article : Google Scholar : PubMed/NCBI
35	Vaisanen MR, Vaisanen T, Jukkola-Vuorinen A, Vuopala KS, Desmond R, Selander KS and Vaarala MH: Expression of Toll-like receptor-9 is increased in poorly differentiated prostate tumors. Prostate. 70:817–824. 2010. View Article : Google Scholar : PubMed/NCBI
36	Kauppila JH, Takala H, Selander KS, Lehenkari PP, Saarnio J and Karttunen TJ: Increased Toll-like receptor 9 expression indicates adverse prognosis in esophageal adenocarcinoma. Histopathology. 59:643–649. 2011. View Article : Google Scholar : PubMed/NCBI
37	Heikki T, Kauppila JH, Soini Y, Selander KS, Vuopala KS, Lehenkari PP, Saarnio J and Karttunen TJ: Toll-like receptor 9 is a novel biomarker for esophageal squamous cell dysplasia and squamous cell carcinoma progression. J Innate Immun. 3:631–638. 2011. View Article : Google Scholar : PubMed/NCBI